TNFSF4 and ovarian carcinoma: Patent application WO2020097409 by Moderna, USA featuresmethodsfor treating ovarian cancer, as well as other cancers such as solidtumors, lymphomas, and epithelial origin cancers, by administeringmRNA encoding an OX40L polypeptide, also known as CD252.